The purpose of this study was to evaluate the association between HER2 amplification level by ISH and treatment outcomes in patients with advanced HER2-positive breast cancer treated with first-line pertuzumab, trastuzumab, and docetaxel. This evidence concerns the gene ERBB2 and breast cancer.